Accessibility Statement Skip Navigation
  • Resources
  • Investor Relations
  • Journalists
  • Agencies
  • Client Login
  • Send a Release
Return to PR Newswire homepage
  • News
  • Products
  • Contact
Search
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News Releases view all

    • News in Focus
        • Browse News Releases

        • All News Releases
        • All Public Company
        • English-only
        • News Releases Overview

        • Multimedia Gallery

        • All Multimedia
        • All Photos
        • All Videos
        • Multimedia Gallery Overview

        • Trending Topics

        • All Trending Topics
    • Business & Money
        • Auto & Transportation

        • Aerospace, Defense
        • Air Freight
        • Airlines & Aviation
        • Automotive
        • Maritime & Shipbuilding
        • Railroads and Intermodal Transportation
        • Supply Chain/Logistics
        • Transportation, Trucking & Railroad
        • Travel
        • Trucking and Road Transportation
        • Auto & Transportation Overview

        • View All Auto & Transportation

        • Business Technology

        • Blockchain
        • Broadcast Tech
        • Computer & Electronics
        • Computer Hardware
        • Computer Software
        • Data Analytics
        • Electronic Commerce
        • Electronic Components
        • Electronic Design Automation
        • Financial Technology
        • High Tech Security
        • Internet Technology
        • Nanotechnology
        • Networks
        • Peripherals
        • Semiconductors
        • Business Technology Overview

        • View All Business Technology

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Financial Services & Investing

        • Accounting News & Issues
        • Acquisitions, Mergers and Takeovers
        • Banking & Financial Services
        • Bankruptcy
        • Bond & Stock Ratings
        • Conference Call Announcements
        • Contracts
        • Cryptocurrency
        • Dividends
        • Earnings
        • Earnings Forecasts & Projections
        • Financing Agreements
        • Insurance
        • Investments Opinions
        • Joint Ventures
        • Mutual Funds
        • Private Placement
        • Real Estate
        • Restructuring & Recapitalization
        • Sales Reports
        • Shareholder Activism
        • Shareholder Meetings
        • Stock Offering
        • Stock Split
        • Venture Capital
        • Financial Services & Investing Overview

        • View All Financial Services & Investing

        • General Business

        • Awards
        • Commercial Real Estate
        • Corporate Expansion
        • Earnings
        • Environmental, Social and Governance (ESG)
        • Human Resource & Workforce Management
        • Licensing
        • New Products & Services
        • Obituaries
        • Outsourcing Businesses
        • Overseas Real Estate (non-US)
        • Personnel Announcements
        • Real Estate Transactions
        • Residential Real Estate
        • Small Business Services
        • Socially Responsible Investing
        • Surveys, Polls and Research
        • Trade Show News
        • General Business Overview

        • View All General Business

    • Science & Tech
        • Consumer Technology

        • Artificial Intelligence
        • Blockchain
        • Cloud Computing/Internet of Things
        • Computer Electronics
        • Computer Hardware
        • Computer Software
        • Consumer Electronics
        • Cryptocurrency
        • Data Analytics
        • Electronic Commerce
        • Electronic Gaming
        • Financial Technology
        • Mobile Entertainment
        • Multimedia & Internet
        • Peripherals
        • Social Media
        • STEM (Science, Tech, Engineering, Math)
        • Supply Chain/Logistics
        • Wireless Communications
        • Consumer Technology Overview

        • View All Consumer Technology

        • Energy & Natural Resources

        • Alternative Energies
        • Chemical
        • Electrical Utilities
        • Gas
        • General Manufacturing
        • Mining
        • Mining & Metals
        • Oil & Energy
        • Oil and Gas Discoveries
        • Utilities
        • Water Utilities
        • Energy & Natural Resources Overview

        • View All Energy & Natural Resources

        • Environ­ment

        • Conservation & Recycling
        • Environmental Issues
        • Environmental Policy
        • Environmental Products & Services
        • Green Technology
        • Natural Disasters
        • Environment Overview

        • View All Environ­ment

        • Heavy Industry & Manufacturing

        • Aerospace & Defense
        • Agriculture
        • Chemical
        • Construction & Building
        • General Manufacturing
        • HVAC (Heating, Ventilation and Air-Conditioning)
        • Machinery
        • Machine Tools, Metalworking and Metallurgy
        • Mining
        • Mining & Metals
        • Paper, Forest Products & Containers
        • Precious Metals
        • Textiles
        • Tobacco
        • Heavy Industry & Manufacturing Overview

        • View All Heavy Industry & Manufacturing

        • Telecomm­unications

        • Carriers and Services
        • Mobile Entertainment
        • Networks
        • Peripherals
        • Telecommunications Equipment
        • Telecommunications Industry
        • VoIP (Voice over Internet Protocol)
        • Wireless Communications
        • Telecommunications Overview

        • View All Telecomm­unications

    • Lifestyle & Health
        • Consumer Products & Retail

        • Animals & Pets
        • Beers, Wines and Spirits
        • Beverages
        • Bridal Services
        • Cannabis
        • Cosmetics and Personal Care
        • Fashion
        • Food & Beverages
        • Furniture and Furnishings
        • Home Improvement
        • Household, Consumer & Cosmetics
        • Household Products
        • Jewelry
        • Non-Alcoholic Beverages
        • Office Products
        • Organic Food
        • Product Recalls
        • Restaurants
        • Retail
        • Supermarkets
        • Toys
        • Consumer Products & Retail Overview

        • View All Consumer Products & Retail

        • Entertain­ment & Media

        • Advertising
        • Art
        • Books
        • Entertainment
        • Film and Motion Picture
        • Magazines
        • Music
        • Publishing & Information Services
        • Radio & Podcast
        • Television
        • Entertainment & Media Overview

        • View All Entertain­ment & Media

        • Health

        • Biometrics
        • Biotechnology
        • Clinical Trials & Medical Discoveries
        • Dentistry
        • FDA Approval
        • Fitness/Wellness
        • Health Care & Hospitals
        • Health Insurance
        • Infection Control
        • International Medical Approval
        • Medical Equipment
        • Medical Pharmaceuticals
        • Mental Health
        • Pharmaceuticals
        • Supplementary Medicine
        • Health Overview

        • View All Health

        • Sports

        • General Sports
        • Outdoors, Camping & Hiking
        • Sporting Events
        • Sports Equipment & Accessories
        • Sports Overview

        • View All Sports

        • Travel

        • Amusement Parks and Tourist Attractions
        • Gambling & Casinos
        • Hotels and Resorts
        • Leisure & Tourism
        • Outdoors, Camping & Hiking
        • Passenger Aviation
        • Travel Industry
        • Travel Overview

        • View All Travel

    • Policy & Public Interest
        • Policy & Public Interest

        • Advocacy Group Opinion
        • Animal Welfare
        • Congressional & Presidential Campaigns
        • Corporate Social Responsibility
        • Domestic Policy
        • Economic News, Trends, Analysis
        • Education
        • Environmental
        • European Government
        • FDA Approval
        • Federal and State Legislation
        • Federal Executive Branch & Agency
        • Foreign Policy & International Affairs
        • Homeland Security
        • Labor & Union
        • Legal Issues
        • Natural Disasters
        • Not For Profit
        • Patent Law
        • Public Safety
        • Trade Policy
        • U.S. State Policy
        • Policy & Public Interest Overview

        • View All Policy & Public Interest

    • People & Culture
        • People & Culture

        • Aboriginal, First Nations & Native American
        • African American
        • Asian American
        • Children
        • Diversity, Equity & Inclusion
        • Hispanic
        • Lesbian, Gay & Bisexual
        • Men's Interest
        • People with Disabilities
        • Religion
        • Senior Citizens
        • Veterans
        • Women
        • People & Culture Overview

        • View All People & Culture

    • Explore Our Platform
    • Plan Campaigns
    • Create with AI
    • Distribute Press Releases
    • Report Results
    • Amplify Content
    • All Products
    • General Inquiries
    • Editorial Bureaus
    • Partnerships
    • Media Inquiries
    • Worldwide Offices
    • Hamburger menu
    • PR Newswire: news distribution, targeting and monitoring
    • Send a Release
      • ALL CONTACT INFO
      • Contact Us

        888-776-0942
        from 8 AM - 10 PM ET

    • Searching for your content...

      No results found. Please change your search terms and try again.

      News Releases

      view all
      Close menu
    • News
    • Products
    • Contact
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • 3 News in Focus
      • 5 Business & Money
      • 5 Science & Tech
      • 5 Lifestyle & Health
      • 1 Policy & Public Interest
      • 1 People & Culture
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content
      • All Products
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices
      • Send a Release
      • Client Login
      • Resources
      • Blog
      • Journalists
      • RSS
      Close submenu (News in Focus) News in Focus
      • Browse News Releases
      • Multimedia Gallery
      • Trending Topics
      Close submenu (Business & Money) Business & Money
      • Auto & Transportation
      • Business Technology
      • Entertain­ment & Media
      • Financial Services & Investing
      • General Business
      Close submenu (Science & Tech) Science & Tech
      • Consumer Technology
      • Energy & Natural Resources
      • Environ­ment
      • Heavy Industry & Manufacturing
      • Telecomm­unications
      Close submenu (Lifestyle & Health) Lifestyle & Health
      • Consumer Products & Retail
      • Entertain­ment & Media
      • Health
      • Sports
      • Travel
      Close submenu (Policy & Public Interest) Policy & Public Interest
      • Policy & Public Interest
      Close submenu (People & Culture) People & Culture
      • People & Culture

      WRN Inhibitors Market Enters Growth Phase with Multiple Early-Stage Clinical Programs Underway | DelveInsight

      DelveInsight Logo

      News provided by

      DelveInsight Business Research, LLP

      Nov 12, 2025, 17:31 ET

      Share this article

      Share this article


      WRN inhibitors are attracting increasing attention as a niche but fast-emerging segment within precision oncology, driven by their role in targeting DNA repair vulnerabilities. Promising candidates, such as NDI-219216, GSK4418959, HRO761, and RO7589831, are in the early stages of clinical development, underscoring both scientific credibility and market opportunity. These therapies are designed to exploit synthetic lethality in MSI-high tumors, offering a precision therapy option for cancers with limited existing treatment options.

      LAS VEGAS, Nov. 12, 2025 /PRNewswire/ -- DelveInsight's WRN Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding of current treatment practices, addressable patient population, which includes top indications such as Colorectal Cancer, Endometrial Cancer, and Solid Tumors. The selected indications are based on approved therapies and ongoing pipeline activity. The report also provides insights into the emerging WRN inhibitors, market share of individual therapies, and current and forecasted market size from 2020 to 2040, segmented into leading markets (the US, EU4, UK, and Japan).

      Key Takeaways from the WRN Inhibitors Market Report

      • The total market size of WRN inhibitors in the leading markets is expected to surge significantly by 2040.
      • The report provides the total potential number of patients in the indications, such as Colorectal Cancer, Endometrial Cancer, and Solid Tumors.
      • Leading WRN inhibitor companies, such as Nimbus Therapeutics, GlaxoSmithKline, Ideaya Biosciences, Novartis Pharmaceuticals, Vividion Therapeutics, MOMA Therapeutics, Roche, and others, are developing novel WRN inhibitors that can be available in the WRN inhibitors market in the coming years. 
      • Some of the key WRN inhibitors in clinical trials include NDI-219216, GSK4418959, HRO761, VVD-214 (RO7589831), MOMA-341, RO7589831, and others.

      Discover which indication is expected to grab the major WRN inhibitors market share @ WRN Inhibitors Market Report

      Key Factors Driving the WRN Inhibitors Market 

      Synthetic Lethality Targeting in MSI Cancers

      WRN inhibitors exploit synthetic lethality by targeting the Werner syndrome helicase (WRN), critical for DNA repair in MSI-H tumors. Tumors with high microsatellite instability rely heavily on WRN for survival due to replication stress and DNA damage, creating an intense therapeutic vulnerability.

      Precision Medicine and Biomarker Development

      Advances in genetic testing and biomarker-driven patient stratification (e.g., MSI and mismatch repair status) enable the identification of patients most likely to benefit from WRN inhibitors, thereby supporting market growth through the adoption of targeted therapy.

      Promising Preclinical and Early Clinical Data

      Multiple WRN inhibitors, such as NDI‑219216 (Nimbus Therapeutics), GSK4418959 (GlaxoSmithKline and Ideaya Biosciences), HRO761 (Novartis Pharmaceuticals), and VVD-214 (RO7589831) (Vividion Therapeutics), have demonstrated potent anti-tumor activity with strong selectivity for MSI tumors, including tumor regression in patient-derived xenograft models and signs of clinical activity in early human trials. This fuels investor and developer confidence.

      WRN Inhibitors Market Analysis

      WRN inhibitors are still in the early stages of development, with no regulatory approvals to date. However, interest in this mechanism is rapidly increasing due to WRN's essential role in DNA repair and genome stability, particularly in microsatellite instability (MSI) tumors, making WRN inhibition a compelling avenue for precision oncology.

      Early clinical candidates, such as NDI-219216, GSK4418959, HRO761, and RO7589831, underscore the growing scientific validation and commercial promise in this space. These molecules are designed to exploit synthetic lethality in MSI-high tumors, providing a targeted treatment option for cancers with limited existing therapeutic options. Furthermore, the potential to combine WRN inhibitors with other agents or extend their application to additional DNA repair–deficient malignancies presents a strong opportunity for therapeutic innovation.

      In summary, WRN inhibitors are emerging as a novel class of precision oncology therapies with the potential to transform cancer treatment. Supported by compelling early-stage data, a robust mechanistic foundation, and rising scientific momentum, this field is well positioned for significant progress as it moves toward clinical proof of concept.

      Learn more about the WRN inhibitors @ WRN Inhibitors Analysis

      WRN Inhibitors Competitive Landscape

      Several early-stage WRN inhibitors are under development by leading biotech and pharma companies, including NDI‑219216 (Nimbus Therapeutics), GSK4418959 (GlaxoSmithKline and Ideaya Biosciences), HRO761 (Novartis Pharmaceuticals), VVD-214 (RO7589831) (Vividion Therapeutics), and others, highlighting growing scientific and commercial interest in this mechanism.

      Nimbus Therapeutics' NDI-219216 is a potent and highly selective non-covalent inhibitor targeting the Werner syndrome helicase, under investigation for the treatment of microsatellite instability-high (MSI-H) tumors. Nimbus Therapeutics is evaluating the compound in a multicenter, open-label Phase I/II clinical study (NCT06898450) involving patients with advanced solid tumors, both MSI-H and non-MSI.

      GlaxoSmithKline and Ideaya Biosciences' IDE275 (GSK959) is positioned as a potential best-in-class WRN inhibitor, demonstrating single-agent tumor regression in MSI-H patient-derived and cell line-derived xenograft models of endometrial, colorectal, and gastric cancers. It is currently being assessed in a Phase I/II clinical program for adults with mismatch repair-deficient (dMMR) or MSI-H solid tumors, including endometrial and colorectal cancers.

      The anticipated launch of these emerging therapies are poised to transform the WRN inhibitors market landscape in the coming years. As these cutting-edge therapies continue to mature and gain regulatory approval, they are expected to reshape the WRN inhibitors market landscape, offering new standards of care and unlocking opportunities for medical innovation and economic growth.

      To know more about WRN inhibitors clinical trials, visit @ WRN Inhibitors Treatment 

      Recent Developments in the WRN Inhibitors Market

      • In July 2025, MOMA Therapeutics announced that the first patient had been dosed in its Phase I clinical trial to assess the safety and tolerability of MOMA-341.
      • In June 2025, Bayer's Vividion Therapeutics secured the global rights from its partner, Roche, to the only covalent WRN inhibitor to have advanced into the clinic. Vividion and Roche have collaborated on the candidate, known as RO7589831, as part of their 2020 partnership. The drug is designed to damage the DNA of cancers by inhibiting WRN, a DNA repair enzyme.
      • In April 2025, Nimbus announced that the Phase I/II trial of NDI-219216 is actively enrolling and dosing participants with advanced solid tumors. Earlier this month, in October 2024, the company presented encouraging preclinical data on NDI-219216 (formerly NTX-452) at the 36th EORTC-NCI-AACR Symposium on Molecular Targets and Cancer Therapeutics.
      • In March 2025, IDEAYA Biosciences announced multiple presentations at the AACR Annual Meeting 2025 for IDE275 (GSK959), including an oral session in the New Drugs on the Horizon series and three poster sessions. The compound has shown selective preclinical efficacy in MSI-H solid tumors and is progressing through a Phase I dose-escalation study in collaboration with GSK.

      What are WRN Inhibitors?

      Werner helicase (WRN) inhibitors represent a growing area of research focused on the WRN protein, which plays a vital role in DNA repair and genome stability. These inhibitors are especially significant in microsatellite instability (MSI) cells, where WRN activity is crucial for maintaining genomic integrity. While no WRN-targeted therapies have received approval to date, this mechanism has attracted considerable scientific attention for its potential to shed light on DNA damage response, cell proliferation, and genomic maintenance processes.

      WRN Inhibitors Epidemiology Segmentation

      The WRN Inhibitors market report is a comprehensive and specialized analysis, offering in-depth epidemiological insights for the study period 2020–2034 across the leading markets. WRN helicase is present in high-MSI tumors, occurring in roughly 15% of colorectal cancer cases. In 2024, the US recorded approximately 150,000 new colorectal cancer cases, the highest among the 7MM, likely due to lifestyle factors, dietary patterns, and extensive screening programs that increase detection.

      The WRN Inhibitors target patient pool is segmented into:

      • Total Cases of Selected Indications for WRN Inhibitors
      • Total Eligible Patient Pool of Selected Indications 
      • Total Treated Cases in the Selected Indication for WRN Inhibitors

      WRN Inhibitors Report Metrics

      Details

      Study Period

      2020–2040

      WRN Inhibitors Report Coverage

      7MM [The United States, the EU-4 (Germany, France, Italy, and Spain), the United Kingdom, and Japan]

      Key Indications Covered in the Report

      Colorectal Cancer, Endometrial Cancer, and Solid Tumors

      Key WRN Inhibitor Companies

      Nimbus Therapeutics, GlaxoSmithKline, Ideaya Biosciences, Novartis Pharmaceuticals, Vividion Therapeutics, MOMA Therapeutics, Roche, and others

      Key WRN Inhibitors

      NDI-219216, GSK4418959, HRO761, VVD-214 (RO7589831), MOMA-341, RO7589831, and others

      Scope of the WRN Inhibitors  Market Report

      • WRN Inhibitors Therapeutic Assessment: WRN Inhibitors current marketed and emerging therapies
      • WRN Inhibitors Market Dynamics: Conjoint Analysis of Emerging WRN Inhibitors Drugs
      • Competitive Intelligence Analysis: SWOT analysis and Market entry strategies
      • Unmet Needs, KOL's views, Analyst's views, WRN Inhibitors Market Access and Reimbursement

      Discover more about WRN inhibitors in development @ WRN Inhibitors Clinical Trials

      Table of Contents

      1

      WRN Inhibitor Market Key Insights

      2

      WRN Inhibitor Market Report Introduction

      3

      Executive Summary of WRN Inhibitors

      4

      Key Events

      5

      Epidemiology and Market Forecast Methodology

      6

      WRN Inhibitors Market Overview at a Glance in the 7MM

      6.1

      WRN Inhibitor Market Share (%) Distribution by Indication in 2024

      6.2

      WRN Inhibitor Market Share (%) Distribution by Indication in 2040

      7

      WRN Inhibitors: Background and Overview

      8

      Treatment and Management

      9

      Target WRN Inhibitor Patient Pool

      9.1

      Key Findings

      9.2

      Assumptions and Rationale: 7MM

      9.3

      Epidemiology Scenario in the 7MM

      9.3.1

      Total Cases of Selected Indication for WRN Inhibitors in the 7MM

      9.3.2

      Total Eligible Patient Pool for WRN Inhibitors in Selected Indications in the 7MM

      9.3.3

      Total Treatable Cases in Selected Indications for WRN Inhibitors in the 7MM

      10

      Emerging WRN Inhibitor Therapies

      10.1

      Key Competitors

      10.2

      NDI-219216: Nimbus Therapeutics

      10.2.1

      Product Description

      10.2.2

      Other developmental activities

      10.2.3

      Clinical development

      10.2.4

      Safety and efficacy

      10.2.5

      Analyst Views

      10.3

      GSK4418959: GlaxoSmithKline and IDEAYA Biosciences

      List to be continued in the report…

      11

      WRN Inhibitors Market: Seven Major Market Analysis

      11.1

      Key Findings

      11.2

      WRN Inhibitor Market Outlook

      11.3

      Key WRN Inhibitor Market Forecast Assumptions

      11.4

      Total Market Size of WRN Inhibitors in the 7MM

      11.5

      The United States WRN Inhibitor Market Size

      11.5.1

      Market Size of WRN Inhibitors by Indication in the United States

      11.5.2

      Market Size of WRN Inhibitors by Therapies in the United States

      11.6

      EU4 and the UK WRN Inhibitor Market Size

      11.7

      Japan WRN Inhibitor Market Size

      12

      SWOT Analysis of WRN Inhibitors

      13

      KOL Views of WRN Inhibitors

      14

      Unmet Needs of WRN Inhibitors

      15

      Market Access and Reimbursement

      15.1

      United States

      15.2

      EU4 and the UK

      15.3

      Japan

      15.4

      Summary and Comparison of Market Access and Pricing Policy Developments in 2025

      15.5

      WRN Inhibitors: Market Access and Reimbursement

      16

      Bibliography

      17

      WRN Inhibitor Market Report Methodology

      Related Reports

      Colorectal Cancer Market

      Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key CRC companies, including Mirati Therapeutics, Exelixis, Enterome, Arcus Biosciences, Lyell Immunopharma, AstraZeneca, Novartis Pharmaceuticals, Surgimab, Numab Therapeutics, SOTIO Biotech, Amgen, Sichuan Baili Pharmaceutical, Qilu Pharmaceutical, Bristol-Myers Squibb, NGM Biopharmaceuticals, Takeda, PureTech, Pfizer, Kezar Life Sciences, Salubris Biotherapeutics, among others.

      Metastatic Colorectal Cancer Market

      Metastatic Colorectal Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key mCRC companies, including Johnson & Johnson Innovative Medicine, Shanghai Henlius Biotech, Inspirna, Treos Bio, Cardiff Oncology, Agenus, Leap Therapeutics, Arcus Biosciences, Enterome, Tizona Therapeutics, Innovative Cellular Therapeutics, among others.

      Endometrial Cancer Market

      Endometrial Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key endometrial cancer companies, including Merck, Karyopharm Therapeutics, AstraZeneca, Daiichi Sankyo, Faeth Therapeutics, Hoffmann-La Roche, Iovance Biotherapeutics, GSK, Eisai, among others.

      Mismatch Repair Deficiency Market

      Mismatch Repair Deficiency Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, as well as the market trends, market drivers, market barriers, and key mismatch repair deficiency companies, including Arcus Biosciences, Gilead Sciences, Medicenna Therapeutics, Novartis, Roche, Merck, Bristol Myers Squibb, among others.

      About DelveInsight

      DelveInsight is a leading Business Consultant and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance. Get hassle-free access to all the healthcare and pharma market research reports through our subscription-based platform PharmDelve.

      Contact Us

      Shruti Thakur
      [email protected]
      +14699457679

      Logo: https://mma.prnewswire.com/media/1082265/3528414/DelveInsight_Logo.jpg

      SOURCE DelveInsight Business Research, LLP

      Modal title

      Also from this source

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Epilepsy Market Set to Grow During the Forecast Period (2026-2036) as Novel Antiseizure Therapies Gain Momentum | DelveInsight

      Recently published Epilepsy Market Insights report includes a comprehensive understanding of current treatment practices, epilepsy emerging drugs,...

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      JAK Inhibitors Market to Register Notable Growth During the Forecast Period (2026-2036) Through Expanding Clinical and Commercial Landscape | DelveInsight

      DelveInsight's JAK Inhibitors Market Size, Target Population, Competitive Landscape & Market Forecast report includes a comprehensive understanding...

      More Releases From This Source

      Explore

      Health Care & Hospitals

      Health Care & Hospitals

      Medical Pharmaceuticals

      Medical Pharmaceuticals

      Biotechnology

      Biotechnology

      News Releases in Similar Topics

      Contact PR Newswire

      • Call PR Newswire at 888-776-0942
        from 8 AM - 9 PM ET
      • Chat with an Expert
      • General Inquiries
      • Editorial Bureaus
      • Partnerships
      • Media Inquiries
      • Worldwide Offices

      Products

      • Explore Our Platform
      • Plan Campaigns
      • Create with AI
      • Distribute Press Releases
      • Report Results
      • Amplify Content

      About

      • About PR Newswire
      • About Cision
      • Careers
      • Accessibility Statement
      • APAC
      • APAC - Simplified Chinese
      • APAC - Traditional Chinese
      • Brazil
      • Canada
      • Czech
      • Denmark
      • Finland
      • France
      • Germany
      • India
      • Indonesia
      • Israel
      • Italy
      • Japan
      • Korea
      • Mexico
      • Middle East
      • Middle East - Arabic
      • Netherlands
      • Norway
      • Poland
      • Portugal
      • Russia
      • Slovakia
      • Spain
      • Sweden
      • United Kingdom
      • Vietnam

      My Services

      • All New Releases
      • Platform Login
      • Data Privacy

      Do not sell or share my personal information:

      • Submit via [email protected] 
      • Call Privacy toll-free: 877-297-8921

      Contact PR Newswire

      Products

      About

      My Services
      • All News Releases
      • Platform Login
      • ProfNet
      Call PR Newswire at
      888-776-0942
      • Terms of Use
      • Privacy Policy
      • Information Security Policy
      • Site Map
      • RSS
      • Cookies
      Copyright © 2026 Cision US Inc.